ACR 2026: 5 Autoimmune CAR-T Abstracts That Move Stocks

Every biotech investor knows ASCO moves stocks. Far fewer screen ACR, the American College of Rheumatology’s annual meeting, and that is the edge. ACR Convergence 2026 runs November 6-11 in Orlando. The trade fires before the podium. Regular abstracts release in October, and the late-breaking slate publishes mid-October with the media embargo lifting November 7 at 10 a.m. Eastern. If you wait for the presenter to step up, the stock has already gapped.

ACR matters more this year than any year in the last decade because of the August reset. Novartis paused its autologous CD19 CAR-T rap-cel across lupus, systemic sclerosis, and myositis after three patients died from immune effector cell-associated hemophagocytic syndrome, or IEC-HS. Bristol Myers Squibb then paused its own autologous zola-cel program over transient inflammatory events. Both were rapid-manufacturing constructs. The question ACR has to answer is whether that safety blowup was specific to those two constructs, or whether it kills the entire off-the-shelf autoimmune cell therapy category. Here are the five names where one dataset answers the question, ranked by stock-moving potential.

1. Kyverna miv-cel: The Autologous Construct That Already Answered the Safety Question

Kyverna Therapeutics closed at $6.81, a $421 million market cap. Its miv-cel (mivocabtagene autoleucel, KYV-101) is an autologous CD19 CAR-T, and its one-year safety record is the cleanest in the field since the reset. On September 24, Kyverna reported one-year data from KYSA-8, its registrational stiff person syndrome trial: as of a July 2026 database lock, 12-month follow-up on 26 SPS patients showed no high-grade cytokine release syndrome, no ICANS, and no cases of IEC-HS. Across more than 100 patients treated in autoimmune disease, the safety profile has held consistent.

The re-rate thesis is that this is the first clean safety read since rap-cel and zola-cel blew up. Kyverna is running a rolling BLA submission on track to complete in the fourth quarter of 2026, so the filing itself is the near-term catalyst, not the conference. A $421 million market cap for the only autoimmune CD19 CAR-T with a clean one-year dataset and an active BLA is a mismatch worth buying into. The abstract to screen for at ACR is the fuller SPS and myasthenia gravis dataset with B-cell reconstitution and durability beyond one year. The risk is that SPS is a niche indication, and the market wants lupus data before it pays up. The full miv-cel SPS durability story and the one-year data release are covered.

2. CRISPR Therapeutics zugo-cel: The Off-the-Shelf Benchmark

CRISPR Therapeutics closed at $54.23, a $5.24 billion market cap, the largest pure-play in autoimmune cell therapy. Its zugo-cel (zugocaptagene geleucel, CTX112) is an allogeneic, CRISPR-edited CD19 CAR-T. The autoimmune read is small but the signal is clean: the first SLE patient, refractory to nine prior therapies, held drug-free DORIS remission through month 12, and the second SLE patient through month 6, with more than 14 patients dosed across lupus, systemic sclerosis, and myositis.

The ACR dataset to screen for is the larger autoimmune cohort with safety. The specific question is whether an allogeneic construct can deliver deep B-cell depletion without the IEC-HS that killed the autologous rapid-manufacturing programs. If it does, CRISPR re-rates as the safest off-the-shelf option and the capital that left the category in August comes back. If it shows the same inflammatory signals, the selloff extends and the theme stays on ice. The risk is venue: CRISPR could hold the update for a hematology meeting instead, and the read-through never lands at ACR. The zugo-cel (CTX112) program status and the three deaths reset are covered.

3. Adicet prula-cel: The $84 Million Lottery Ticket

Adicet Bio closed at $9.02, an $84 million market cap. Its prula-cel (prulacabtagene leucel, ADI-001) is an allogeneic gamma delta CAR-T that targets CD20 rather than CD19, a meaningful differentiation: CD20 depletion reaches the B-cell lineage at the source, including plasmablasts. The company reports Phase 1 SLE and lupus nephritis data on Monday, September 28, covering 22 patients with a minimum of six months of follow-up, 13 of whom have 12 months or more.

That September 28 readout lands a full month before ACR, so the abstract to screen for at the meeting is the durability and any expansion cohort. The re-rate thesis is arithmetic. At $84 million, prula-cel is priced as if the data is a coin flip, while a clean allogeneic gamma delta read with durable remissions would re-rate the name several-fold. This is the top reward-per-dollar name on the list, and a binary one. Watch the September 28 readout first, then screen ACR for follow-up. The prula-cel primer is covered.

4. argenx efgartigimod: The Legacy Mechanism Holding the Franchise

argenx closed at $959.49, a $60 billion market cap, and it is the non-CAR-T name on this list. Efgartigimod is an FcRn blocker that lowers pathogenic IgG autoantibodies without touching the B cells themselves, a fundamentally safer mechanism than cell therapy. The Phase 3 ALKIVIA trial in autoimmune myositis hit its primary endpoint: a 15.4-point greater improvement in mean Total Improvement Score at week 52 versus placebo (47.95 vs 32.56, p=0.0011), the first Phase 3 win for any FcRn therapy in the disease. The immune-mediated necrotizing myopathy subgroup was significant at 14.8 points (p=0.0048); the smaller dermatomyositis subgroup missed significance at 14.5 points (p=0.1093).

The ACR read is the detailed ALKIVIA dataset plus Sjogren’s and systemic sclerosis follow-up. The honest framing is that argenx already moved on the August 17 topline, and at $60 billion the incremental read is modest. This is the anchor that holds the autoimmune franchise while the CAR-T names sort themselves out, not a name you buy for the ACR pop. The ALKIVIA myositis win is covered.

5. Alumis envudeucitinib: The Failure That Makes the Cure Thesis

Alumis closed at $7.10, a $919 million market cap, and its inclusion is the contrarian move. Envudeucitinib, a TYK2 inhibitor, missed its primary endpoint (BICLA, a composite lupus disease-activity measure) at Week 48 and key secondary endpoints such as SRI-4 in the Phase 2b LUMUS trial in systemic lupus erythematosus, yet Alumis is proceeding to Phase 3 anyway on a prespecified subgroup of patients with a high interferon gene signature. The read-through cuts both ways. On one side, it shows how hard it is to beat placebo in SLE with a conventional small molecule, which is exactly why the drug-free remission promised by CAR-T is so valuable. On the other, it is a reminder that a mechanism can look clean in a subgroup and still fail a registrational trial.

The ACR item is the subgroup data and the Phase 3 design. This is not a stock you buy for a re-rate; it is the cautionary baseline that makes the CAR-T cure thesis worth paying for. The LUMUS miss analysis is covered.

The Mega-Cap Filter

Novartis rap-cel and BMS zola-cel will dominate the ACR safety narrative, but at roughly $200 billion and $128 billion market caps respectively, a pause or a resumption moves each ticker roughly zero basis points. The three-death reset is context for the small-cap trade, not a trade itself. The same logic applies to any JNJ nipocalimab or other FcRn franchise update: at mega-cap scale, one rheumatology dataset does not move the stock.

The Catalyst-Consumed Caveat

Two of these catalysts resolve before ACR even opens. Kyverna already dropped its one-year data on September 24, and Adicet reports on September 28. The ACR value for both is the follow-up, not the topline. Verify the September readouts before you treat either name as an ACR binary.

The playbook is the same one that applies to every conference: abstract release is the trade date, not the podium session. Position size is 1-2% of portfolio per binary event, and IV crush after the abstract drop is real whether the data is good or bad. The conference trading guide and the full autoimmune catalyst shelf are covered.

The verdict: Kyverna miv-cel is the name to own into ACR. It already has the clean safety answer, the one-year durability, and an active rolling BLA, all at $421 million. CRISPR zugo-cel is the second name to watch, because a clean allogeneic read re-opens the category. Adicet is the lottery ticket. Everything else is context.